European Biotech Acquisition Corp. (EBAC) is a Blank Checks company listed on NASDAQ. There were no new wire items for EBAC in the last 30 days. The most recent was published Mar 13, 2023.
Latest news
25 items- SECSEC Form 15-12G filed by European Biotech Acquisition Corp.15-12G - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECSEC Form 25-NSE/A filed by European Biotech Acquisition Corp. (Amendment)25-NSE/A - European Biotech Acquisition Corp. (0001841258) (Subject)
- SECEuropean Biotech Acquisition Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECSEC Form 10-K filed by European Biotech Acquisition Corp.10-K - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECEuropean Biotech Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECSEC Form DEFA14A filed by European Biotech Acquisition Corp.DEFA14A - European Biotech Acquisition Corp. (0001841258) (Filer)
- 13D/GSEC Form SC 13G filed by European Biotech Acquisition Corp.SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
- SECEuropean Biotech Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
- 13D/GSEC Form SC 13G filed by European Biotech Acquisition Corp.SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
- 13D/GSEC Form SC 13G/A filed by European Biotech Acquisition Corp. (Amendment)SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)
- SECSEC Form DEFM14A filed by European Biotech Acquisition Corp.DEFM14A - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECSEC Form 425 filed by European Biotech Acquisition Corp.425 - European Biotech Acquisition Corp. (0001841258) (Subject)
- SECEuropean Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECSEC Form 425 filed by European Biotech Acquisition Corp.425 - European Biotech Acquisition Corp. (0001841258) (Subject)
- SECEuropean Biotech Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECSEC Form 10-Q filed by European Biotech Acquisition Corp.10-Q - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECEuropean Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
- NEWSOculis SA And European Biotech Acquisition Corp Announce Business Combination Agreement To Create Nasdaq-lListed BioPharmaceutical Company Driving Breakthrough Innovations In OphthalmologyOculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populations Net proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the
- PROculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmologyOculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populationsNet proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the fir
- SECSEC Form 10-Q filed by European Biotech Acquisition Corp.10-Q - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECSEC Form 10-Q filed by European Biotech Acquisition Corp.10-Q - European Biotech Acquisition Corp. (0001841258) (Filer)
- SECSEC Form 10-K filed by European Biotech Acquisition Corp.10-K - European Biotech Acquisition Corp. (0001841258) (Filer)
- 13D/GSEC Form SC 13G/A filed by European Biotech Acquisition Corp. (Amendment)SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)
- 13D/GSEC Form SC 13G filed by European Biotech Acquisition Corp.SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
- 13D/GSEC Form SC 13G/A filed by European Biotech Acquisition Corp. (Amendment)SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)
EBAC FAQ
7 questionsWhat does European Biotech Acquisition Corp. do?
European Biotech Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands.What is the latest news on EBAC?
Quantisnow has not tracked any new filings, ratings or press releases for EBAC in the last 30 days. The most recent wire item was published on March 13, 2023.Where does EBAC stock trade?
European Biotech Acquisition Corp. (EBAC) is listed on NASDAQ.What sector and industry is EBAC in?
European Biotech Acquisition Corp. operates in the Finance sector, Blank Checks industry.When did European Biotech Acquisition Corp. go public?
European Biotech Acquisition Corp. (EBAC) completed its IPO in 2021.What companies are similar to EBAC?
Notable peers in the same industry include TACO (Berto Acquisition Corp.), PRE (Prenetics Global Limited), OXSQ (Oxford Square Capital Corp.), ILLU (Illumination Acquisition Corp I), INV (Innventure Inc.). Compare EBAC side-by-side with any of them on Quantisnow.How can I track EBAC on Quantisnow?
Quantisnow aggregates European Biotech Acquisition Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EBAC to receive live email and push alerts on every new disclosure.